US Stem Cell Inc (USRM)

[Poor Man -]

Disturbing Revenue Trend

Despite the company trying to claim that it reports positive financial results (it isn't, in my opinion), they actually fail to mention that revenue declined from $711k in Q1 to $678k in Q2.

This decline in quarter over quarter revenue was actually a very significant 4.6% decrease in revenue in just three months. This is especially serious for a company that requires substantial growth in order to become self-sustaining. Of course this is not only a disturbing quarterly trend, but it also means further dilution to shareholders as the company will likely need to rely on dilutive financing to fund it's operating deficits.